Want a free pharma latte? Show your ID
By Tracy Staton
You've heard that there's no free lunch, but no free coffee? One of the trends noticed at last weekend's American Society of Clinical Oncology meeting was careful policing of just who took free lattes. No Vermonters were allowed at the Pfizer coffee machine, thanks to that state's strict rules on pharma gifts for physicians--and no Minnesotans, either.
And those doctors who did collect a cup of joe? They'll see their names on the Pfizer website, a company spokesman promised Reuters. "Any gift, even a cup of coffee, is posted on our Pfizer website for disclosure purposes and to provide complete clarity."
One international drugmaker even limited coffee handouts to doctors with international ID badges. A woman stood guard, in fear that the FDA's handout police would come calling.
It's a far cry from the ASCO exhibit floor of the past, where doctors could pick up all sorts of drugmaker tchotchkes. Apparently, pharma companies are really taking the new PhRMA gift guidelines seriously. In some views, too seriously. "This is getting to the point of absurdity," a deputy CMO at the American Cancer Society remarked to Reuters.
Please feel free to share your thoughts....
Tuesday, June 8, 2010
Thursday, May 27, 2010
Immunology Drug Development Physicians
The world of social media offers unprecedented ability for those with common interests to connect........
Immunology Drug Development Physicians is a LinkedIn Group for Physicians supporting Drug Development in the growing and evolving Immunology arena.
This group is for physicians working in Immunology Drug Development. Immunology is an area of drug development that is continuing to expand in scope; indications being explored include but are not limited to Rheumatology, Psoriatic Arthritis, Lupus, Scleroderma, Respiratory and Oncology. The growth of monoclonal drug development will continue to fuel this expansion.
The goal of this forum is for physicians to discuss the scientific and business aspects of immunology drug development; to create a space for physicians to discuss their experiences and challenges.
We encourage you to exchange your thoughts, and seek advice from colleagues.
We encourage you to exchange your thoughts, and seek advice from colleagues.
Drug Safety / Pharmacovigilance / Pharmacoepidemiology Physicians
The world of social media offers unprecedented ability for those with common interests to connect........
Drug Safety / Pharmacovigilance / Pharmacoepidemiology Physicians is a LinkedIn Group for Physicians working in the areas of Drug Safety, Pharmacovigilance Pharmacoepidemiology and Risk Management inside of the pharmaceutical and biotechnology companies.
The goal of this group is to create a forum to discuss the scientific and business aspects of these disciplines. To create a space for physicians to discuss their professional experiences and the challenges they face.
We encourage you to exchange your thoughts, and seek advice from colleagues.
Friday, May 14, 2010
LEGAL UPDATE – From Bob Style NAPS Attorney.
LEGAL UPDATE – From Bob Style NAPS Attorney.
HIRE Act provides tax incentives for hiring the unemployed
The Hiring Incentives to Restore Employment Act (“Hire Act”) is a recently enacted federal law which provides certain tax benefits to those employers who hire the unemployed. It may be of interest to those engaged in temporary staffing, as well as to clients of placement firms.
The first tax credit applies to employers who hire the unemployed at some point between February 3, 2010 and January 1, 2011. The credit is for an amount equal to the employer’s portion of the social security tax.
The employee must complete and file with you an IRS form (W-11) in which he or she states, under penalties of perjury, that the employee has worked less than 40 hours in the most recent 60 day period. The employee cannot be hired to replace another employee who was terminated without cause, and cannot be related to anyone owning at least a 50% interest in the employer.
If the employer keeps the employee on the payroll for 52 consecutive weeks, and the employee earns in the second 26 weeks of the period, at least 80% of the earnings for the first 26 weeks, then the employer becomes eligible for a $1,000 tax credit in 2011.
This information was provided by NAPS through Bob Styles Legal Updates email.
HIRE Act provides tax incentives for hiring the unemployed
The Hiring Incentives to Restore Employment Act (“Hire Act”) is a recently enacted federal law which provides certain tax benefits to those employers who hire the unemployed. It may be of interest to those engaged in temporary staffing, as well as to clients of placement firms.
The first tax credit applies to employers who hire the unemployed at some point between February 3, 2010 and January 1, 2011. The credit is for an amount equal to the employer’s portion of the social security tax.
The employee must complete and file with you an IRS form (W-11) in which he or she states, under penalties of perjury, that the employee has worked less than 40 hours in the most recent 60 day period. The employee cannot be hired to replace another employee who was terminated without cause, and cannot be related to anyone owning at least a 50% interest in the employer.
If the employer keeps the employee on the payroll for 52 consecutive weeks, and the employee earns in the second 26 weeks of the period, at least 80% of the earnings for the first 26 weeks, then the employer becomes eligible for a $1,000 tax credit in 2011.
This information was provided by NAPS through Bob Styles Legal Updates email.
Monday, April 12, 2010
Jobs as a Bargaining Chip.....
Paper: Roche, Novartis threaten to leave UK
Drugmakers may not have the power to force the U.K. to pay for their meds, but they do have one massive bargaining chip: Jobs. Witness Swiss drugmakers Novartis and Roche, which reportedly are threatening to pull out of Britain and move some 5,000 jobs abroad.
The threats came in personal meetings with U.K. ministers, who've been traveling the world to placate drugmakers angered by, among other things, drug pricing for the National Health Service, The Guardian reports.
In fact, the officials have mounted a "vigorous charm offensive" to keep multinational drugmakers from leaving the country, according to the paper, which got access to government documents about the situation. As part of that effort, ministers and repesentatives of the cost-effectiveness watchdog NICE have visited pharma execs at their headquarters in Japan, the U.S. and Europe. They've been visiting companies they fear they're most at risk of losing--including Roche and Novartis.
Roche, for one, objected to government efforts to cut drug prices. The U.K. "price squeeze" could well spread beyond Britain's borders, the company says, because many other countries use U.K. prices to set their own. If Roche pulled out of the U.K., it might lose 3 percent of its business, but would "safeguard pricing levels at the remaining 97 percent," the paper reports.
At the officials' meeting with Novartis, the company hinted that it might like some government incentives to help pay for an expansion and upgrade at one Liverpool-area vaccine plant. And company officials warned that the company might move some of their trials out of the country, because the NHS system is too slow, making trials too expensive.
Roche, for its part, says it has "no plans" to leave the U.K.; it's just working with the government to persuade Britain to adopt more new meds, it says in a statement emailed to Dow Jones. Novartis wouldn't comment.
Please feel free to share your thoughts.....
Drugmakers may not have the power to force the U.K. to pay for their meds, but they do have one massive bargaining chip: Jobs. Witness Swiss drugmakers Novartis and Roche, which reportedly are threatening to pull out of Britain and move some 5,000 jobs abroad.
The threats came in personal meetings with U.K. ministers, who've been traveling the world to placate drugmakers angered by, among other things, drug pricing for the National Health Service, The Guardian reports.
In fact, the officials have mounted a "vigorous charm offensive" to keep multinational drugmakers from leaving the country, according to the paper, which got access to government documents about the situation. As part of that effort, ministers and repesentatives of the cost-effectiveness watchdog NICE have visited pharma execs at their headquarters in Japan, the U.S. and Europe. They've been visiting companies they fear they're most at risk of losing--including Roche and Novartis.
Roche, for one, objected to government efforts to cut drug prices. The U.K. "price squeeze" could well spread beyond Britain's borders, the company says, because many other countries use U.K. prices to set their own. If Roche pulled out of the U.K., it might lose 3 percent of its business, but would "safeguard pricing levels at the remaining 97 percent," the paper reports.
At the officials' meeting with Novartis, the company hinted that it might like some government incentives to help pay for an expansion and upgrade at one Liverpool-area vaccine plant. And company officials warned that the company might move some of their trials out of the country, because the NHS system is too slow, making trials too expensive.
Roche, for its part, says it has "no plans" to leave the U.K.; it's just working with the government to persuade Britain to adopt more new meds, it says in a statement emailed to Dow Jones. Novartis wouldn't comment.
Please feel free to share your thoughts.....
Tuesday, March 16, 2010
Would like to Congratulate her Fellow Honorees
Would like to Congratulate her Fellow Honorees for the 2010 Long Island Business News Top 50 Most Influential Women in Business Awards
http://libn.com/top-50-most-influential-women-in-business-awards/
http://libn.com/top-50-most-influential-women-in-business-awards/
Wednesday, February 24, 2010
Physicians in the Pharmaceutical Industry
The world of social media offers unprecedented ability for those with common interests to connect........
Physicians in the Pharmaceutical Industry is a LinkedIn Group for Physicians employed inside of the Pharmaceutical industry. Choosing an alternative career path to clinical medicine can be rewarding while also offering challenges.
The goal of this forum is to discuss the scientific and business aspects of drug development and to create a space for physicians to discuss their professional experiences. Utilizing medical training in a non-traditional capacity can create unique bonds and experiences.
Join here:
http://www.linkedin.com/groupRegistration?gid=2753832
We encourage you to exchange your thoughts, and seek advice from colleagues.
Subscribe to:
Posts (Atom)
Posts
